EE200100667A - CD20 vastaste antikehade kasutamine transplantaadi peremehevastase reaktsiooni raviks - Google Patents

CD20 vastaste antikehade kasutamine transplantaadi peremehevastase reaktsiooni raviks

Info

Publication number
EE200100667A
EE200100667A EEP200100667A EEP200100667A EE200100667A EE 200100667 A EE200100667 A EE 200100667A EE P200100667 A EEP200100667 A EE P200100667A EE P200100667 A EEP200100667 A EE P200100667A EE 200100667 A EE200100667 A EE 200100667A
Authority
EE
Estonia
Prior art keywords
antibodies
versus
host disease
treat graft
graft
Prior art date
Application number
EEP200100667A
Other languages
English (en)
Estonian (et)
Inventor
Golay Josee
Introna Martino
Rambaldi Alessandro
Biondi Andrea
Original Assignee
Consiglio Nazionale Delle Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Delle Ricerche filed Critical Consiglio Nazionale Delle Ricerche
Publication of EE200100667A publication Critical patent/EE200100667A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EEP200100667A 1999-06-11 2000-06-07 CD20 vastaste antikehade kasutamine transplantaadi peremehevastase reaktsiooni raviks EE200100667A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
PCT/EP2000/005212 WO2000076542A1 (en) 1999-06-11 2000-06-07 Use of antibodies against cd20 for the treatment of the graft versus host disease

Publications (1)

Publication Number Publication Date
EE200100667A true EE200100667A (et) 2003-02-17

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100667A EE200100667A (et) 1999-06-11 2000-06-07 CD20 vastaste antikehade kasutamine transplantaadi peremehevastase reaktsiooni raviks

Country Status (26)

Country Link
US (1) US20070014785A1 (it)
EP (1) EP1185299B1 (it)
JP (1) JP2003501482A (it)
KR (1) KR20020026455A (it)
CN (1) CN1253208C (it)
AU (1) AU774206B2 (it)
BG (1) BG106193A (it)
CA (1) CA2376288A1 (it)
CZ (1) CZ20014450A3 (it)
DE (1) DE60033030T2 (it)
DK (1) DK1185299T3 (it)
EE (1) EE200100667A (it)
ES (1) ES2278616T3 (it)
HK (1) HK1043549B (it)
HU (1) HUP0201600A3 (it)
IL (1) IL146934A0 (it)
IS (1) IS6195A (it)
IT (1) ITMI991299A1 (it)
NO (1) NO20016035L (it)
NZ (1) NZ515992A (it)
PL (1) PL352860A1 (it)
PT (1) PT1185299E (it)
SK (1) SK18132001A3 (it)
TR (1) TR200103581T2 (it)
WO (1) WO2000076542A1 (it)
ZA (1) ZA200110004B (it)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1043312B (en) 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2347241T3 (es) * 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
WO2005000901A2 (en) 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
AU2004256042A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
US8530187B2 (en) * 2004-03-22 2013-09-10 The Ohio State University Research Foundation Methods for transfecting natural killer cells
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
ES2426817T3 (es) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
EP1902320B1 (en) 2005-05-20 2010-03-10 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
CA2616386A1 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals Inc. Single dose use of cd20-specific binding molecules
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
JP5403752B2 (ja) * 2007-06-22 2014-01-29 北海道公立大学法人 札幌医科大学 移植片対宿主疾患の検査および治療方法
MX354993B (es) 2007-07-09 2018-03-28 Genentech Inc Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
US7879984B2 (en) 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
JP2011500715A (ja) 2007-10-16 2011-01-06 ザイモジェネティクス， インコーポレイテッド 自己免疫疾患の治療のためのＢＬｙＳ阻害剤および抗ＣＤ２０剤の組合せ
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
TW201438738A (zh) * 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
BR112012002974B1 (pt) 2009-08-11 2022-06-07 Genentech, Inc Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
JP6771492B2 (ja) 2015-05-30 2020-10-21 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU719930B2 (en) * 1996-05-31 2000-05-18 Genetic Therapy, Inc. Prevention of graft-versus-host disease with T-cells including polynucleotides encoding negative selective markers
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
JP2003501482A (ja) 2003-01-14
SK18132001A3 (sk) 2002-05-09
ITMI991299A0 (it) 1999-06-11
HUP0201600A2 (en) 2002-08-28
NZ515992A (en) 2004-01-30
NO20016035L (no) 2002-02-11
HUP0201600A3 (en) 2005-04-28
CN1355712A (zh) 2002-06-26
CN1253208C (zh) 2006-04-26
ZA200110004B (en) 2003-02-26
NO20016035D0 (no) 2001-12-10
ES2278616T3 (es) 2007-08-16
HK1043549B (zh) 2006-09-01
BG106193A (bg) 2002-08-30
KR20020026455A (ko) 2002-04-10
HK1043549A1 (en) 2002-09-20
PL352860A1 (en) 2003-09-08
ITMI991299A1 (it) 2000-12-11
EP1185299A1 (en) 2002-03-13
DK1185299T3 (da) 2007-05-21
EP1185299B1 (en) 2007-01-17
CZ20014450A3 (cs) 2002-04-17
US20070014785A1 (en) 2007-01-18
IS6195A (is) 2001-12-10
IL146934A0 (en) 2002-08-14
TR200103581T2 (tr) 2002-08-21
PT1185299E (pt) 2007-03-30
CA2376288A1 (en) 2000-12-21
AU774206B2 (en) 2004-06-17
WO2000076542A1 (en) 2000-12-21
AU5530300A (en) 2001-01-02
DE60033030T2 (de) 2007-05-31
DE60033030D1 (de) 2007-03-08

Similar Documents

Publication Publication Date Title
EE200100667A (et) CD20 vastaste antikehade kasutamine transplantaadi peremehevastase reaktsiooni raviks
CY2022005I1 (el) Βελτιστοποιημενα αντισωματα που στοχευουν to cd19
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
AR027976A1 (es) Anticuerpos humanos para cd154
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
CY2012019I2 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
CY2009019I1 (el) Αντισωματα για την ανθρωπινη il-1 βητα
DE60121958D1 (de) Frühdiagnose von konformationellen erkrankungen
NO20031218D0 (no) Kombinasjonsterapi for behandling av autoimmunsykdommer ved anvendelse av B-celle reduserende/immunregulerende antistoff kombinasjon
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
PL1648513T3 (pl) Zastosowanie przeciwciał z optymalizowaną adcc do leczenia pacjentów słabo odpowiadających na leczenie przeciwciałami
CY2012003I1 (el) Αντισωματα που συνδεονται ανοσοειδικως προς blys
IL158831A0 (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
MA25519A1 (fr) Traitement de matieres minerales
AU2003295411A8 (en) Human monoclonal antibodies to heparanase
AU8390301A (en) Antibodies to human MCP-1
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
EP1063592A4 (en) DOCUMENT PROCESSOR
EP1542721A4 (en) MODIFIED "S" ANTIBODIES
IL160928A0 (en) Use of histamine to treat liver disease
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
EP1556499A4 (en) FOR CARCINOGENIC BACTERIA SPECIFIC MONOCLONAL ANTIBODIES